Royal Bank of Canada
LRMR icon

Royal Bank of Canada’s Larimar Therapeutics LRMR Stock Holding History

Royal Bank of Canada’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Sell
757
-744
-50% -$2.97K ﹤0.01% 6599
2025
Q4 		$6K Sell
1,501
-66,877
-98% -$260K ﹤0.01% 6644
2025
Q3 		$220K Sell
68,378
-32,519
-32% -$122K ﹤0.01% 5033
2025
Q2 		$292K Buy
100,897
+100,843
+186,746% +$233K ﹤0.01% 4879
2025
Q1 		$0 Sell
54
-932
-95% -$2.95K ﹤0.01% 7053
2024
Q4 		$3K Sell
986
-6,254
-86% -$41.3K ﹤0.01% 6652
2024
Q3 		$47K Buy
7,240
+3,273
+83% +$26.3K ﹤0.01% 5727
2024
Q2 		$29K Buy
3,967
+3,373
+568% +$25.8K ﹤0.01% 5909
2024
Q1 		$4K Sell
594
-8,207
-93% -$63.9K ﹤0.01% 6510
2023
Q4 		$40K Buy
8,801
+1,923
+28% +$6.49K ﹤0.01% 6083
2023
Q3 		$27K Buy
6,878
+4,203
+157% +$15.9K ﹤0.01% 6080
2023
Q2 		$8K Buy
+2,675
New +$10.9K ﹤0.01% 6545
2022
Q4 		– Sell
-42
Closed – – 7503
2022
Q3 		$0 Buy
+42
New +$105 ﹤0.01% 7664
2021
Q2 		– Sell
-91
Closed -$1K – 7593
2021
Q1 		$1K Sell
91
-17
-16% -$309 ﹤0.01% 7308
2020
Q4 		$2K Sell
108
-20
-16% -$401 ﹤0.01% 6863
2020
Q3 		$2K Sell
128
-51
-28% -$646 ﹤0.01% 6323
2020
Q2 		$2K Buy
179
+3
+2% +$35 ﹤0.01% 6288
2020
Q1 		$1K Buy
176
+26
+17% +$342 ﹤0.01% 6455
2019
Q4 		$2K Buy
150
+59
+65% +$564 ﹤0.01% 6558
2019
Q3 		$1K Buy
91
+58
+176% +$636 ﹤0.01% 6471
2019
Q2 		$0 Sell
33
-8
-20% -$213 ﹤0.01% 7035
2019
Q1 		$1K Buy
41
+8
+24% +$410 ﹤0.01% 6654
2018
Q4 		$2K Sell
33
-224
-87% -$22.1K ﹤0.01% 6448
2018
Q3 		$36K Buy
257
+32
+14% +$3.88K ﹤0.01% 5391
2018
Q2 		$28K Sell
225
-3,320
-94% -$282K ﹤0.01% 5400
2018
Q1 		$317K Sell
3,545
-13
-0.4% -$1.1K ﹤0.01% 4018
2017
Q4 		$197K Buy
3,558
+1
+0% +$45 ﹤0.01% 4433
2017
Q3 		$150K Buy
3,557
+6
+0.2% +$250 ﹤0.01% 4724
2017
Q2 		$149K Sell
3,551
-75
-2% -$3.84K ﹤0.01% 4541
2017
Q1 		$202K Sell
3,626
-68
-2% -$3.38K ﹤0.01% 4328
2016
Q4 		$141K Buy
3,694
+161
+5% +$6.53K ﹤0.01% 4695
2016
Q3 		$140K Sell
3,533
-183
-5% -$8.31K ﹤0.01% 4647
2016
Q2 		$268K Buy
3,716
+3,505
+1,661% +$277K ﹤0.01% 4196
2016
Q1 		$17K Buy
211
+103
+95% +$8.13K ﹤0.01% 5554
2015
Q4 		$8K Sell
108
-63
-37% -$10.1K ﹤0.01% 6037
2015
Q3 		$66K Buy
171
+146
+584% +$65.8K ﹤0.01% 5001
2015
Q2 		$10K Buy
+25
New +$10.5K ﹤0.01% 6046
2015
Q1 		– Sell
-3
Closed -$1K – 6294
2014
Q4 		$1K Buy
+3
New +$773 ﹤0.01% 6043

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Royal Bank of Canada's LRMR Position: Q1 2026 in Review

Royal Bank of Canada reduced its Larimar Therapeutics (LRMR) stake by 50% in Q1 2026, selling an estimated $2.97K and leaving 757 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #6599.

Royal Bank of Canada first reported a position in LRMR in Q4 2014 and has held it in 38 quarters since. The position peaked at $317K in Q1 2018. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Royal Bank of Canada held 757 shares of Larimar Therapeutics worth $3K as of Q1 2026.
  • Royal Bank of Canada sold 744 Larimar Therapeutics shares in Q1 2026, an estimated $2.97K.
  • Larimar Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6599 holding.
  • Royal Bank of Canada first reported a position in Larimar Therapeutics in Q4 2014 and has held it in 38 quarters since.
  • Royal Bank of Canada's Larimar Therapeutics position peaked at $317K in Q1 2018.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.